📊 PEN Key Takeaways
Is Penumbra Inc (PEN) a Good Investment?
Penumbra demonstrates solid fundamentals with strong revenue growth (+17.5%) and excellent operational cash flow ($174.9M). The company maintains a fortress balance sheet with zero debt, exceptional liquidity (6.64x current ratio), and world-class gross margins (67.1%). However, flat net income growth despite strong top-line expansion signals margin compression concerns that warrant monitoring.
Why Buy Penumbra Inc Stock? PEN Key Strengths
- Strong revenue growth of 17.5% YoY in medical device sector
- Exceptional gross margin of 67.1% demonstrates pricing power and operational efficiency
- Fortress balance sheet with zero long-term debt and $186.9M cash position
- Robust free cash flow generation of $174.9M with 12.5% FCF margin
- Excellent liquidity ratios (6.64x current, 4.29x quick) provide financial flexibility
- Medical device industry exposure provides defensive growth characteristics
PEN Stock Risks: Penumbra Inc Investment Risks
- Net income flat (0% YoY) despite 17.5% revenue growth indicates margin compression or cost pressures
- Operating margin of 13.5% is low relative to 67.1% gross margin, suggesting elevated operating expenses
- EPS growth (+1155.6%) is driven by share buybacks rather than operational improvement
- ROE (12.4%) and ROA (9.7%) are moderate, indicating capital efficiency concerns
- Lack of long-term debt detail may indicate financing structure not fully transparent
Key Metrics to Watch
- Operating margin trend and ability to leverage gross margin gains into operating income
- Net income growth acceleration and organic margin expansion
- Free cash flow sustainability and capital allocation decisions
- Operating expense ratio trends to identify cost control initiatives
Penumbra Inc (PEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.64x current ratio provides a solid financial cushion.
PEN Profit Margin, ROE & Profitability Analysis
PEN vs Healthcare Sector: How Penumbra Inc Compares
How Penumbra Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Penumbra Inc Stock Overvalued? PEN Valuation Analysis 2026
Based on fundamental analysis, Penumbra Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Penumbra Inc Balance Sheet: PEN Debt, Cash & Liquidity
PEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Penumbra Inc's revenue has grown significantly by 88% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.32 reflects profitable operations.
PEN Revenue Growth, EPS Growth & YoY Performance
PEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $301.0M | $11.0M | $-0.51 |
| Q2 2025 | $299.4M | $11.0M | $1.15 |
| Q1 2025 | $278.7M | $11.0M | $0.28 |
| Q3 2024 | $270.9M | $8.6M | $0.23 |
| Q2 2024 | $261.5M | $8.6M | $0.48 |
| Q1 2024 | $241.4M | $8.6M | $0.22 |
| Q3 2023 | $213.7M | $79.0K | $-0.06 |
| Q2 2023 | $208.3M | $79.0K | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Penumbra Inc Dividends, Buybacks & Capital Allocation
PEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Penumbra Inc (CIK: 0001321732)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 6, 2026 | 4 | xslF345X06/wk-form4_1775520139.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773790417.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773790361.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773790331.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773790301.xml | View → |
❓ Frequently Asked Questions about PEN
What is the AI rating for PEN?
Penumbra Inc (PEN) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PEN's key strengths?
Claude: Strong revenue growth of 17.5% YoY in medical device sector. Exceptional gross margin of 67.1% demonstrates pricing power and operational efficiency.
What are the risks of investing in PEN?
Claude: Net income flat (0% YoY) despite 17.5% revenue growth indicates margin compression or cost pressures. Operating margin of 13.5% is low relative to 67.1% gross margin, suggesting elevated operating expenses.
What is PEN's revenue and growth?
Penumbra Inc reported revenue of $1.4B.
Does PEN pay dividends?
Penumbra Inc does not currently pay dividends.
Where can I find PEN SEC filings?
Official SEC filings for Penumbra Inc (CIK: 0001321732) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PEN's EPS?
Penumbra Inc has a diluted EPS of $4.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PEN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Penumbra Inc has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PEN stock overvalued or undervalued?
Valuation metrics for PEN: ROE of 12.4% (sector avg: 15%), net margin of 12.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PEN stock in 2026?
Our dual AI analysis gives Penumbra Inc a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PEN's free cash flow?
Penumbra Inc's operating cash flow is $238.7M, with capital expenditures of $63.7M. FCF margin is 12.5%.
How does PEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 12.7% (avg: 12%), ROE 12.4% (avg: 15%), current ratio 6.64 (avg: 2).